Non-Hodgkin Lymphoma

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2016 ASCO Annual Meeting

Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial. Lorenz H. Trumper


A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL). Adrienne Alise Phillips


Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. James L. Rubenstein


Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). Mathias J. Rummel


Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. Pieternella J. Lugtenburg


PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). Thomas E. Witzig


Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). Andrew M. Evens


Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. David W. Scott


Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. David Matthew Kurtz


Long-term follow-up of the PI3Kδ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. Howard A. Burris


Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. Michael Crump


Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study. Nicolas Mounier


Participation in clinical trials to improve outcomes of patients with relapsed lymphoma. Grzegorz S. Nowakowski


Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST). Grzegorz S. Nowakowski


Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL. Florian Zettl


Effect of antiviral therapy on overall survival in hepatitis c virus-infected patients with diffuse large b-cell lymphoma. Jeff Hosry


Outcomes and prognostic factors of radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) for newly diagnosed, localized extranodal NK/T-cell lymphoma, nasal type (ENKL): a cooperative study in Japan. Motoko Yamaguchi


Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL). Kunihiro Tsukasaki


Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. Theresa H.M. Keegan


Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL). Narendranath Epperla


Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin’s lymphoma (R-R NHL). Wojciech Jurczak


Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma. Gita Thanarajasingam


Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system. Karen Leroy


The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. Constantine Si Lun Tam


A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. Ahmed Sawas


Lymphoma-associated mortality in the German HIV-lymphoma cohort study. Marcus Hentrich


Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). Issa F. Khouri


Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM). Jonas Paludo


A phase II prospective clinical study of the “sandwich” protocol, VDLP combined with concurrent radiation and cisplatin in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Li Zhang


Noninvasive molecular subtyping and risk stratification of DLBCL. Florian Scherer


Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. Robert W. Chen


Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110. Jean-Marie Michot


Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies—Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing. Paul A. Hamlin


Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. Francine M. Foss


Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). Sattva Swarup Neelapu


Application of multi-agent CT among patients with leg-type primary cutaneous B-cell lymphoma. Sarah Swati Pai


Sandwich-like gemcitabine, dexamethasone, and cisplatin(GDP) chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, upper aerodigestive tract natural killer/T-cell lymphoma. Shu Tian


A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results. Madeleine Duvic


Outcomes of diffuse large b-cell lymphoma with MYC and/or BCL2 protein expression treated with intensive chemotherapy. Amir Issa


Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). Stephen J. Schuster


Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma. I Brian Greenwell


Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma. Andrew David Zelenetz


Deferred treatment as a viable option for selected patients with mantle cell lymphoma. Oscar Calzada


Outcomes of patients with diffuse large B-cell lymphoma treated with immunochemotherapy based on cell of origin. Avyakta Kallam


EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC). Line Srour


Clinicopathologic features and survival outcomes of secondary diffuse large b-cell lymphoma after a primary solid malignancy: SEER propensity-matched analysis. Muhammad Saad Hamid


Efficacy and safety of examethasone, high dose cytarabine, and carboplatin (DHAC) with and without rituximab (R) as a salvage regimen for relapsed/refractory (R/R) lymphoma. Jeffrey Baron


Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma. Sung Hsin Kuo


Integrated infectious toxicity analysis of the BTK inhibitor ibrutinib. James Michael Pauff


The incidence, prognosis and survival of primary breast lymphoma: A SEER experience. Vivek Kumar


Incidence and risk factors for ibrutinib associated atrial fibrillation. Josephine Ngozi Emole


Pre-cancer cardiovascular risk factors and anthracycline-related cardiotoxicity among non-Hodgkin lymphoma survivors. Talya Salz


Prognostic impact of CD3 infiltrating t-cells in the tumor microenvironment with clinical factors for solid organ transplant (SOT) recipients with post-transplant lymphoproliferative disorders (PTLD). Ryan Stubbins


Localized orbital adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation and rituximab: a single institute experience. Maria Chaudhry


Single center experience of 90Y-Ibritumomab tiuxetan in the older population with non-hodgkin lymphoma. Vaibhav Agrawal


NK/T cell lymphoma in the U.S: A population-based study using the National Cancer Database from 1998-2012. Amritha C. Karkera


Rituximab-induced hepatitis C virus reactivation in HCV-positive patients with diffuse large B-cell lymphoma. Rasha Mohamed Haggag


Flt3L-based in situ vaccination for the treatment of lymphoma. Linda Hammerich


A new prognostic model for nasal-type, extranodal natural killer/T cell lymphoma. Na Li


Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated with R-ICE based on dual expression of MYC and BCL2. Joshua M. Allen


The prognostic impact of serum albumin in double hit/double expressing aggressive B cell lymphomas: A pilot study evaluating SAAB scoring system. Chetasi Talati


Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: A Peruvian experience. Luis Ernesto Cuellar Ponce de León


Phase I/II study of an anti-CD20-interleukin-2 immunocytokine DI-Leu16-IL2 in patients with relapsed b-cell lymphoma (NHL). Frederick Lansigan


Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan. Kenichi Ishizawa


Patterns of recurrence in primary central nervous system lymphoma: Mechanistic inferences. Prakash Ambady


Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma. Carla Casulo


Successful treatment in primary central nervous system lymphoma. Erden Atilla


Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga). Adrienne Alise Phillips


Role of FDG-PET/CT and gastrointestinal endoscopy in the staging of diffuse large B-cell lymphoma (DLBCL): Expanded data. Tadahiro Honda


Differential response to radiation treatment in molecular subtypes of diffuse large B-Cell lymphoma (DLBCL). Elaine Patricia Lunsford


Development of non-Hodgkin lymphoma as a second primary cancer in patients with chronic hepatitis C virus infection. Minas P. Economides


Clinical significance of gastrointestinal involvement in human immunodeficiency virus (HIV) patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Abdul Rafeh Naqash


Association of activated BCR and PI3K pathways with responses and longer PFS to single-agent copanlisib in heavily pretreated patients with indolent and aggressive NHL. LI Liu


Phase I study of recombinant human interleukin-18 (IL-18) in combination with ofatumumab after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoma. Michael J. Robertson


Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma. Sean I. Tracy


The serum albumin and gender in patients with low risk NCCN-IPI diffuse large B-cell lymphoma. Branimir Spassov


Synergistic cytotoxic effects of selinexor and chloroquine phosphate in mantle cell lymphoma. Yongyi Zhang


A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study. Kiyohiko Hatake


A rare manifestation: Primary mediastinal large-b cell lymphoma. Erden Atilla


Association between cocaine use and hematological malignancies. Amandeep Singh Aujla


Bone marrow involvement in mantle cell lymphoma: An immunophenotyping analysis with clinicopathologic correlation from a tertiary care center in North India. CHANDAN KRUSHNA DAS


Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma. Jason R. Westin


A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs). Philippe Armand


A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study. Jason R. Westin


FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen. Nathan Hale Fowler


Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma. Daniel Jeffrey Landsburg


A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL). Ki Y. Chung


First-in-class small molecule ONC201 in b-cell malignancies. Hun Ju Lee


Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Franck Morschhauser


OAsIs: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma. Steven Le Gouill


A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT). Robert W. Chen